Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
| العنوان: | Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research |
|---|---|
| المؤلفون: | Edmund K. Waller, David J. Inwards, Baldeep Wirk, Wael Saber, Hillard M. Lazarus, Bipin N. Savani, Mehdi Hamadani, Parameswaran Hari, David A. Rizzieri, Jeanette Carreras, Mitchell S. Cairo, Timothy S. Fenske, Jack W. Hsu, Robert Peter Gale, Rammurti T. Kamble, A.K. Klein, Gregory A. Hale, Kwang Woo Ahn, Dipnarine Maharaj, David I. Marks, Harry C. Schouten, John Gibson |
| المساهمون: | Interne Geneeskunde, RS: GROW - School for Oncology and Reproduction |
| المصدر: | Biology of Blood and Marrow Transplantation, 19(4), 625-631. Elsevier Science |
| بيانات النشر: | Elsevier Science, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Adult, Male, Oncology, medicine.medical_specialty, Transplantation Conditioning, International Cooperation, medicine.medical_treatment, Reduced intensity conditioning, Lymphoma, Mantle-Cell, Hematopoietic stem cell transplantation, Graft-versus-host disease, Article, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Myeloablative conditioning, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Transplantation, Homologous, Longitudinal Studies, Survival analysis, Aged, Non-Hodgkin lymphoma, Transplantation, Chemotherapy, business.industry, Remission Induction, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Myeloablative Agonists, medicine.disease, Chemorefractory disease, Survival Analysis, 3. Good health, Surgery, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, Mantle cell lymphoma, Bone marrow, business, 030215 immunology |
| الوصف: | Patients with chemorefractory mantle cell lymphoma (MCL) have a poor prognosis. We used the Center for International Blood and Marrow Transplant Research database to study the outcome of 202 patients with refractory MCL who underwent allogeneic hematopoietic cell transplantation (allo-HCT) using either myeloablative (MA) or reduced-intensity/nonmyeloablative conditioning (RIC/NST), during 1998-2010. We analyzed nonrelapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall survival (OS). Seventy-four patients (median age, 54 years) received MA, and 128 patients (median age, 59 years) received RIC/NST. Median follow-up after allo-HCT was 35 months in the MA group and 43 months in the RIC/NST group. At 3 years post-transplantation, no significant between-group differences were seen in terms of NRM (47% in MA versus 43% in RIC/NST; P = .68), relapse/progression (33% versus 32%; P = .89), PFS (20% versus 25%; P = .53), or OS (25% versus 30%; P = .45). Multivariate analysis also revealed no significant between-group differences in NRM, relapse, PFS, or OS; however, receipt of a bone marrow or T cell–depleted allograft was associated with an increased risk of NRM and inferior PFS and OS. Our data suggest that despite a refractory disease state, approximately 25% of patients with MCL can attain durable remission after allo-HCT, and conditioning regimen intensity does not influence outcome of allo-HCT. |
| اللغة: | English |
| تدمد: | 1523-6536 1083-8791 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e368e7da7607649f60fcf2ffcb5517b0Test https://cris.maastrichtuniversity.nl/en/publications/5794a21f-9dbc-47ce-9a06-d304faa2e79dTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e368e7da7607649f60fcf2ffcb5517b0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15236536 10838791 |
|---|